美股异动丨诺华制药盘前跌3%，Q3核心净利润43.3亿美元，低于预期

Core Viewpoint - Swiss pharmaceutical giant Novartis (NVS.US) experienced a pre-market decline of 3%, trading at $125.27, following the release of its third-quarter financial results which showed mixed performance against market expectations [1] Financial Performance - Novartis reported third-quarter net sales of $13.91 billion, slightly above the forecast of $13.88 billion [1] - The core earnings per share were $2.25, just below the expected $2.26 [1] - Core net profit reached $4.33 billion, missing the forecast of $4.42 billion [1] Future Guidance - The company reaffirmed its full-year guidance for 2025, maintaining expectations for high single-digit sales growth and low double-digit core operating profit growth [1]